URL has been copied successfully!
Shares of ImmunityBio Inc. (NASDAQ:IBRX) are climbing with conviction during Wednesday’s session.
This momentum follows an announcement regarding the company’s clinical pipeline and manufacturing outlook.
Clinical Data Showdown at AUA 2026
The company confirmed it will present new comparative data at the American Urological Association Annual Meeting (AUA 2026).
The presentations focus on ANKTIVA plus BCG for bladder cancer.
The surge builds on recent commercial wins.
In April, ImmunityBio launched ANKTIVA in Saudi Arabia for bladder and lung cancer. This rapid rollout occurred within two months of a key regional partnership.
Analyst Perspective on IL-15
Founder Patrick Soon-Shiong …
Please follow us:
This post was originally published here
